SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced agitationTel-Aviv, June 02, 2023 -- SciSparc Ltd. ,... | June 2, 2023

Related Keywords

Israel ,Alexander Kaplan ,Adi Zuloff Shani ,Scisparc Ltd ,Nasdaq ,Exchange Commission ,Company Or Scisparc ,Sophie Abraham Stuchynski Israeli Alzheimer Medical Center ,Abraham Stuchynski Israeli Alzheimer ,Medical Center ,Cohen Mansfield Agitation Inventory ,Edinburgh Feeding Evaluation ,Dementia Scale ,Mini Mental State Exam ,Sleep Disorder Inventory ,Chief Technology Officer ,Open Label Trial ,Efficacy Trend ,Tourette Syndrome ,Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Scisparc Stock Exchange ,News ,Information ,Press Release ,Topline ,Results ,Sing ,The ,Pet ,Primary ,End ,Secondary ,Emonstrating ,Thigh ,Safety ,Profile ,Educed ,Pune ,023 ,Cisparc Sprc Il0010951403 ,